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receptor in normal physiology and dis-
ease require in-depth study. For example, 
generation of mice with genetic deletion 
of the renin/prorenin receptor gene is 
needed. Also, analysis of the actions of 
renin and of prorenin in mesangial cells 
from mice with genetic deletions of dif-
ferent components of the renin–angi-
otensin system may facilitate elucidation 
of the receptor-mediated (that is, angi-
otensin-independent) effects of renin 
and prorenin. Animals lacking angi-
otensin-I receptors, converting enzyme, 
or angiotensinogen are available, and 
their mesangial cells could be used.
In sum, a signifi cant body of evidence 
now indicates that activation of the 
renin–angiotensin system (Figure 1)can 
contribute to the induction and/or pro-
gression of renal and cardiovascular dis-
ease by at least three direct mechanisms 
(that is, independently of the hyperten-
sive eff ect of the system): (1) by direct 
activation of angiotensin receptors by 
Ang II; (2) by activation of the enzymatic 
action of prorenin and enhancement of 
renin’s catalytic activity upon binding 
of these proteins to the renin/prorenin 
receptor; and (3) as shown by Huang et al, 
by direct activation of the renin/prorenin 
receptor and generation of TGF-β. Need-
less to say, all these pathogenic mecha-
nisms raise the intriguing question of 
why normal physiological conditions in 
which the renin–angiotensin system is 
markedly and chronically activated (for 
example, with a low-sodium diet), and 
in which plasma renin and prorenin as 
well as Ang II are markedly elevated, are 
not associated with disease. Answering 
this important question would clarify the 
mechanisms by which these hormones 
contribute to disease.
Although pharmacological blockers of 
the renin–angiotensin system are clearly 
eff ective in many renal and cardiovascu-
lar diseases, their eff ectiveness is limited, 
and exciting novel therapeutic avenues 
are likely to open through research on 
receptor-mediated renin and prorenin 
actions. In addition, because inhibitors 
of the converting enzyme are currently 
among the most frequently prescribed 
antihypertensive medications, in view 
of the results of Huang et al., an analysis 
of the potential harmful eff ects of the 
markedly elevated concentrations of 
plasma renin caused by these drugs is 
urgently needed.
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Hypoxia-inducible factors: where, 
when and why?
JM Gleadle1, DR Mole1 and CW Pugh1
Hypoxia-inducible factor (HIF) is a family of transcription factors that 
regulate the homeostatic response to oxygen deprivation during 
development, physiological adaptation, and pathological processes such 
as ischemia and neoplasia. Our understanding of the function of different 
HIF isoforms is being advanced by understanding the processes that 
regulate their activity, learning where and when they are expressed and 
what genes they regulate.
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Hypoxia-inducible factor-1 (HIF-1) is an 
oxygen-regulated transcriptional complex, 
originally identifi ed by its role in the con-
trol of erythropoietin gene expression in 
response to changes in oxygen tension. Th e 
original HIF components were identifi ed 
aft er affi  nity purifi cation of proteins from 
hypoxic cells capable of binding the oxy-
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gen-regulated erythropoietin 3′ enhancer 
DNA sequence. Th e genes encoding these 
proteins were identifi ed as a novel α chain 
known as HIF-1α and a β chain that was 
found to be identical to the previously 
described aryl hydrocarbon receptor 
nuclear translocator, which is constitu-
tively expressed.1,2 Subsequent work has 
defi ned two further HIFα chains, HIF-2α 
and the much less well studied HIF-3α, 
one splice variant of which was originally 
identifi ed as inhibitory PAS protein 1.
Since the identifi cation of HIF-1, it has 
become clear that the HIF complexes have 
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a much broader role in oxygen homeos-
tasis than simply regulation of eryth-
ropoietin. Th ey control the expression 
of a large number of oxygen-regulated 
genes with functions in diverse processes 
including angiogenesis, metabolism, and 
apoptosis.1,2 Th e identifi cation of multi-
ple hypoxically regulated HIFα isoforms 
raises obvious questions about their func-
tional roles and the selective pressures that 
have led to their evolution. Recent stud-
ies on HIF-1α and HIF-2α, including the 
paper by Bernhardt et al. in this issue,3 are 
beginning to illuminate this debate.
A further renal link arises from the dis-
covery that mutations in the von Hippel-
Lindau (VHL) gene (which occur in the 
majority of sporadic renal-cell carcinomas 
and underlie VHL disease) are associated 
with HIF activation.4 Th is led to the eluci-
dation of the mechanism of oxygen sens-
ing that controls the regulation of HIF in 
all cells. Regulation of HIF complexes is 
mediated by two distinct but similar post-
translational mechanisms. HIFα chain 
abundance is decreased in the presence 
of oxygen by enzymatic hydroxylation 
of two critical prolyl residues within the 
HIFα proteins, which is accomplished by 
a family of three HIF prolyl hydroxylases 
(PHD1, PHD2, and PHD3) and leads to 
VHL E3 ligase-dependent ubiquitylation 
and subsequent proteasomal degrada-
tion. Similarly, when oxygen is available, 
coactivator recruitment is blocked by 
factor inhibiting HIF (FIH)-mediated 
hydroxylation of an asparaginyl residue of 
HIFα. All four of these HIF hydroxylase 
enzymes are oxygen- and 2-oxoglutarate-
dependent dioxygenases; when oxygen 
availability falls, their activity is limited, 
their inhibitory eff ects are removed, HIF 
complexes are activated, and gene expres-
sion increases. Again, the presence of 
multiple HIF hydroxylases raises ques-
tions about their possible redundancy 
and diverse roles. Indeed, these oxygen-
sensing enzymes show diff erential pat-
terns of organ expression, intracellular 
localization, inducibility by exogenous 
stimuli, and substrate selectivity.2
Th e mechanisms regulating the abun-
dance and activity of HIF-1α and HIF-2α 
isoforms are largely concordant, although 
not identical. Th is is refl ected in striking 
sequence similarity in critical functional 
regions, with minor sequence diff erences 
presumably explaining features that, 
although subtle, may be very signifi cant 
biologically, such as precise targeting of 
individual prolyl residues by particular 
prolyl hydroxylase enzymes. Th ere is also 
high homology between the HIF-1α and 
HIF-2α isoforms at the domains involved 
in DNA binding and dimerization. How-
ever, relatively large parts of these protein 
molecules show low levels of sequence 
homology/identity, suggesting that these 
regions of the diff erent isoforms contribute 
diff ering functional capabilities, presum-
ably by interacting with other proteins in a 
cell type- or stimulus-dependent manner.
Evidence for diff erential roles of HIF-
1α and HIF-2α comes from their dif-
fering patterns of organ expression, and 
the different cell types within organs 
that express each α isoform. HIF-2α 
was originally reported to have a very 
restricted pattern of expression in the 
mouse endothelium, contrasting with 
a wide distribution of HIF-1α expres-
sion, and resulting in its original naming 
as endothelial PAS protein 1. Recently, 
distinct expression patterns have been 
demonstrated by immunohistochemistry 
in cell lines and adult tissues, and it has 
become clear that HIF-2α is more widely 
expressed than originally reported. In 
the hypoxic kidney, this work has shown 
HIF-2α expression in the erythropoietin-
producing interstitial fi broblasts, whereas 
HIF-1α is the dominant form expressed 
in tubular epithelial cells.5
Further evidence of distinct functional 
roles has arisen from studies of knockout 
mice, in which the phenotypes of HIF-
1α and HIF-2α knockouts are diff erent. 
HIF-1α knockout mice suff er embryonic 
lethality with enhanced mesenchymal-
cell death and defects in angiogenesis that 
involve both the yolk sac and embryonic 
tissues. By contrast, HIF-2α knockout 
mice have a variable phenotype, with some 
homozygotes surviving to the perinatal 
period. Diff erent reports have indicated 
problems with vascular remodeling; cat-
echolamine production; lung maturation 
and surfactant production; and fatty acid 
oxidation.6 Defects in kidney development 
in these mice have not been investigated 
in depth, as it is diffi  cult to disentangle 
primary eff ects from the secondary con-
sequences of vascular abnormalities. How-
ever, important new work by Bernhardt et 
al3 goes some way toward redressing this, 
reporting differing patterns of expres-
sion of HIF-1α and HIF-2α proteins in 
the normoxic fetal kidney. Th is extends 
the understanding of the developmental 
roles of the HIFα proteins, suggesting dif-
ferential functions in tubular and vascular 
genesis and perhaps a synergistic role in 
formation of glomeruli.
To understand these diff ering roles it will 
be important to defi ne the patterns of gene 
expression elicited by each HIF isoform. 
Additional evidence of functional dis-
parity comes from studies of those genes 
that are selectively activated by individual 
HIFα isoforms. Specifi c examples of this 
include the discordant expression of car-
bonic anhydrase IX, dominantly driven by 
HIF-1α, and erythropoietin, dominantly 
driven by HIF-2α.7,8 Microarray techno-
logy is allowing more complete descrip-
tions of gene expression, and this has 
increased the number of known HIF-
2α-responsive genes, although genes that 
respond solely to HIF-2α appear to be 
substantially rarer than those that respond 
only to HIF-1α. Th e report by Bernhardt 
et al.3 of colocalization of HIF-2α with 
the hypoxically regulated endoglin gene 
product (the gene mutated in hereditary 
hemorrhagic telangiectasia (Rendu-
Osler-Weber syndrome)) provokes the 
speculations that endoglin may be another 
HIF-2α-responsive gene and that endoglin 
might have a role in renal cancer patho-
genesis. Th e mechanisms responsible for 
selective HIFα gene regulation and the tis-
sue specifi city of VHL-associated malig-
nancies are subjects of active study.
In addition to the diff erent physiologi-
cal functions of the HIFα isoforms, there 
appear to be diff erences in the action of 
HIF-1 and HIF-2 in the pathogenesis 
of renal cancer. In the kidneys of VHL 
patients, where HIF is activated because 
of genetic mutation rather than envi-
ronmental factors, the earliest lesions in 
both proximal and distal tubules express 
HIF-1α protein but not HIF-2α protein, 
whereas HIF-2α protein is more abundant 
in later tumor nests, which tend to have a 
distal tubular phenotype/location and to 
be more aggressive.9 In keeping with this, 
many VHL-negative renal cancer cell lines, 
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including those derived from metastases, 
show preferential expression of functional 
HIF-2α over HIF-1α. Additionally, a fur-
ther increase in HIF-2α levels enhances 
growth of renal cancer xenograft s, whereas 
overexpression of HIF-1α inhibits it.10,11
Diff erences in HIF isoform expression 
and function are also manifest in other 
tumor types, presumably refl ecting the 
net selective advantage of the particular 
spectrum of downstream genes activated 
in a particular cellular background by 
environmental factors. In tumors derived 
from ES cells, variable eff ects of loss of 
HIF-1α expression on solid tumor growth 
have been reported, probably depending 
on the balance of eff ects on microenvi-
ronmental hypoxia, apoptosis, and stress-
induced proliferation.12,13 More recently, 
studies on teratomas derived from ES 
cells in which an HIF-2α allele has been 
knocked in at the HIF-1α locus indicate 
that HIF-2α promotes tumor growth 
more eff ectively than HIF-1α.14 In keep-
ing with this, a recent study of melanoma 
patients has reported that, in multivariate 
analysis, HIF-2α staining is an independ-
ent indicator of poor prognosis whereas 
HIF-1α staining is not.15
Tumor development often involves 
reversion to a fetal or embryonic cel-
lular phenotype, with earlier markers 
generally indicating a more aggressive 
phenotype. In the fetal kidney, tubular 
HIF-1α expression is seen in normoxia, 
but this disappears once nephrogenesis is 
complete. Whether HIF-2α contributes 
at an earlier stage of renal development 
than that studied by Bernhardt et al.3 is 
unknown. However, the role of HIF-2 in 
renal vasculogenesis that they describe is 
of particular interest given the highly vas-
cular nature of VHL-associated tumors.
Understanding the functional dif-
ferences between the HIFα isoforms 
and their roles in tumor formation is 
a prerequisite for attempts to manipu-
late this important homeostatic mecha-
nism to therapeutic advantage, be that 
to enhance endogenous erythropoietin 
production, aff ect tumor growth, facili-
tate therapeutic angiogenesis in ischemic 
tissues, or help preserve tissues for trans-
plantation. Th e work reported here by 
Bernhardt et al.3 represents another 
important contribution in dissecting 
the developmental, physiological, and 
pathological roles of HIF.
REFERENCES
1. Semenza GL. Hypoxia-inducible factor 1: master 
regulator of O2 homeostasis. Curr Opin Genet Dev 
1998; 8: 588–594.
2. Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF 
hydroxylases. Nat Rev Mol Cell Biol 2004; 5: 343–354.
3. Bernhardt WM, Schmitt R, Rosenberger C et al. 
Expression of hypoxia-inducible transcription 
factors in developing human and rat kidneys. 
Kidney Int 2006; 69: 114–122. 
4. Maxwell PH, Wiesener MS, Chang GW et al. 
The tumour suppressor protein VHL targets 
hypoxia-inducible factors for oxygen-dependent 
proteolysis. Nature 1999; 399: 271–275.
5. Rosenberger C, Mandriota SJ, Jurgensen JS et al. 
Expression of hypoxia-inducible factor-1α and 
-2α in hypoxic and ischemic rat kidneys. J Am Soc 
Nephrol 2002; 13: 1721–1732.
6. Giaccia AJ, Simon MC, Johnson R. The biology 
of hypoxia: the role of oxygen sensing in 
development, normal function, and disease. Genes 
Dev 2004; 18: 2183–2194.
7. Sowter HM, Raval, RR, Moore, J et al. Predominant 
role of hypoxia-inducible transcription factor (Hif )-
1α versus Hif-2α in regulation of the transcription. 
Cancer Res 2003; 63: 6130–6134.
8. Warnecke C, Zaborowska Z, Kurreck J et al. 
Differentiating the functional role of hypoxia-
inducible factor (HIF)-1alpha and HIF-2alpha 
(EPAS-1) by the use of RNA interference: 
Acute renal failure outcomes in 
children and adults
J Radhakrishnan1 and K Kiryluk1
Acute renal failure (ARF) in hospitalized patients remains associated 
with significant morbidity and mortality. Most reports have detailed 
the in-hospital outcomes in ARF patients. This commentary focuses on 
the outcomes (including quality of life) of ARF patients, both adults and 
children, after discharge from the hospital.
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With rapid advances in medical tech-
nology, the epidemiology of acute renal 
failure (ARF) has dramatically changed. 
Over the past few decades, obstetrical 
and traumatic causes of ARF have con-
tinued to decline, with a correspond-
ing increase in the number of elderly 
patients with complicated medical and 
surgical conditions.1 Th us, the typical 
ARF patient at this time possesses a large 
burden of comorbid illnesses and exten-
sive extrarenal complications.2 Despite 
major advances in dialysis and continu-
ous renal replacement therapies, the 
mortality rate from ARF has not changed. 
Th e adult mortality rates average approx-
imately 50% and have remained stable 
over the past 50 years.3 Th e outcome is 
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